Posterior Uveitis Market

Market Overview: 

The 7 major posterior uveitis markets reached a value of USD 438.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 723.4 Million by  2035, exhibiting a growth rate (CAGR) of 4.68% during 2025-2035.

The posterior uveitis market has been comprehensively analyzed in IMARC's new report titled "Posterior Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Posterior uveitis is a vision-threatening inflammatory disease that occurs in the posterior segment of the eye, comprising the choroid, retina, and optic nerve. It is a multifaceted and heterogeneous condition that can be caused by infectious etiologies like toxoplasmosis, cytomegalovirus, tuberculosis, and syphilis or by non-infectious autoimmune diseases like sarcoidosis, Behçet's disease, and multiple sclerosis. If left untreated, the disease can result in severe vision impairment, thus necessitating early diagnosis and early treatment. Clinical features of posterior uveitis include blurred vision, floaters, pain, photophobia, and, in the advanced form, irreversible loss of vision. Given its multi-factorial etiology, the diagnosis involves the integration of clinical assessment, fundoscopy, optical coherence tomography (OCT), fluorescein angiography, and laboratory investigations to establish underlying etiologies. Since it is long-standing and chronic in nature, posterior uveitis needs extended management protocols so that complications are avoided, namely retinal detachment, macular edema, and optic neuropathy, focusing on the role of good-treatment modalities.

The increasing incidence of infectious and non-infectious posterior uveitis is one of the key drivers for the growth of the market. Autoimmune disorders such as Behçet's disease, sarcoidosis, multiple sclerosis, and Vogt-Koyanagi-Harada syndrome are strong drivers for the prevalence of disease, for which long-term immunosuppressive therapy is needed. Infectious causes such as cytomegalovirus, toxoplasmosis, tuberculosis, and syphilis have also been implicated with posterior uveitis, requiring antimicrobial or antiviral therapy. Increasing worldwide burden of disease of these conditions, as well as aging population demography and growing awareness of ocular disease, further drives marketplace demand. Entry of biologic agents, e.g., TNF inhibitors adalimumab and infliximab and IL blockers, has significantly accelerated disease treatment via targeted therapy with less systemic adverse effects compared with conventional corticosteroids and immunosuppressants. Moreover, advancements in sustained-release intravitreal implants such as fluocinolone acetonide and dexamethasone provide prolonged inflammatory control with a reduced requirement of frequent dosing and optimal patient compliance. Another trend affecting market dynamics is the growing preference towards local corticosteroid injections as opposed to systemic therapy due to lower systemic side effects and improved treatment efficacy in localized inflammation.

IMARC Group's new report provides an exhaustive analysis of the posterior uveitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the posterior uveitis market in any manner.

Recent Developments:

• In April 2024, the NEPTUNE Phase II trial presented that 29% of the patients receiving 45 mg brepocitinib had treatment failure at week 24, reflecting notable efficacy in non-infectious uveitis.
• In June of 2023, the MERIT trial demonstrated that intravitreal dexamethasone implants decreased central subfield thickness by 35% at 12 weeks in uveitic macular edema patients, better than methotrexate and ranibizumab.

Key Highlights:

• Posterior uveitis prevalence varies globally, with rural Tamil Nadu reporting 59 per 10,000 individuals aged 40+, highlighting geographic and environmental influences.
• Uveitis prevalence differs by region and condition, with Taiwan reporting 19.4 per 10,000 individuals, showing no strong gender predilection.
• Certain posterior uveitis types, like APMPPE, predominantly affect individuals aged 20-40, indicating age-specific susceptibility.
• While not fatal, posterior uveitis causes significant visual impairment, emphasizing the need for early detection and treatment.
• Linked to conditions like sarcoidosis and Behçet’s disease, posterior uveitis requires comprehensive management of underlying diseases.

Drugs:

Humira (adalimumab) is an FDA-approved biologic agent for treatment of adults with non-infectious intermediate, posterior, and panuveitis. It is a TNF-α antagonist that inhibits tumor necrosis factor-alpha (TNF-α), suppresses inflammation, and manages disease progression. Clinical trials proved that there was significantly less risk of treatment failure than with placebo.

Ozurdex is a biodegradable intravitreal device that releases 0.7 mg of dexamethasone, a corticosteroid, directly to the posterior segment of the eye. It very effectively decreases inflammation due to non-infectious posterior uveitis, enhancing visual acuity and reducing swelling of the retina.

YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg is a small, non-bioerodible implant to treat posterior segment chronic non-infectious uveitis. It releases a continuous, low-dose corticosteroid directly within the eye for 36 months, lowering inflammation and potentially lowering the incidence of flare-ups and treatment sessions.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the posterior uveitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the posterior uveitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current posterior uveitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the posterior uveitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the posterior uveitis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the posterior uveitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of posterior uveitis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of posterior uveitis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of posterior uveitis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035​) with posterior uveitis across the seven major markets?
• What is the size of the posterior uveitis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of posterior uveitis?
• What will be the growth rate of patients across the seven major markets?

Posterior Uveitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for posterior uveitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the posterior uveitis market?
• What are the key regulatory events related to the posterior uveitis market?
• What is the structure of clinical trial landscape by status related to the posterior uveitis market?
• What is the structure of clinical trial landscape by phase related to the posterior uveitis market?
• What is the structure of clinical trial landscape by route of administration related to the posterior uveitis market?